Mitochondrially targeted anti-cancer drugs modulate the mitochondrial genome. Successful cancer management requires novel therapeutical approaches. This project will test the effect of a new class of compounds that target mitochondria, the powerhouse of the cells, where they suppress expression of mitochondrial genes. By this mechanism, cancers that are resistant to apoptosis induction can be inhibited.
Centre Of Research Excellence In Medicines Intelligence
Funder
National Health and Medical Research Council
Funding Amount
$2,500,000.00
Summary
The NHMRC Centre of Research Excellence in Medicines Intelligence is a co-ordinated research program that will accelerate the development and translation of evidence on prescribed medicines use and outcomes for regulators and payers. The CRE is perfectly placed to embrace the national ‘call to action’ from the Health Minister's recent announcement to establish Quality Use of Medicine Safety as a National Health Priority.
A new Src, PKCdelta and Akt regulated protease activated receptor system in metastasis. In contrast with localised cancer which can often be cured, curative treatment is generally not possible for cancer that has spread. This project will characterise a protein that drives the spread of cancer and to develop new approaches to treat patients at risk of developing these aggressive tumours that spread to other organs.
An Investigation Of The Involvement Of Clotting Factors In Abdominal Aortic Aneurysm (AAA) Progression Within A Mouse Model
Funder
National Health and Medical Research Council
Funding Amount
$189,401.00
Summary
Early stage weakening of the main abdominal artery is present in ~100,000 Australians and currently has no accepted therapy. Development of drug therapies which limit progression of the weakening process is urgently needed. In this study involvement of the clotting cascade in artery weakening will be investigated. The study have been planned in order to identify new strategies which can be developed as treatments for artery weakening in patients.
Heparan sulphate mimetics: Versatile tools for chemical biology. This project aims to develop chemical tools to study heparan sulphate-binding proteins. Heparan sulphate is a complex polysaccharide that is ubiquitously expressed on mammalian cells and interacts with proteins to mediate numerous biological and pathological functions. These interactions are poorly understood. This project will use homogeneous, structurally defined compounds to study heparan sulphate and its binding partners in bio ....Heparan sulphate mimetics: Versatile tools for chemical biology. This project aims to develop chemical tools to study heparan sulphate-binding proteins. Heparan sulphate is a complex polysaccharide that is ubiquitously expressed on mammalian cells and interacts with proteins to mediate numerous biological and pathological functions. These interactions are poorly understood. This project will use homogeneous, structurally defined compounds to study heparan sulphate and its binding partners in biology. This is expected to lead to a better, molecular-level understanding of these fundamental processes, and may have future applications in biotechnology and drug development.Read moreRead less
Chemical proteomics: proteomics with no detection limit. Half of all drugs are derived from natural products, yet little is known about how most achieve their therapeutic action. This project aims to develop a methodology to rapidly uncover drug-protein interactions and pave the way for faster drug development and a better understanding of drug action.
EGFR-directed radioimmunotherapy combined with chemotherapy and DNA repair inhibition: development towards clinical application for aggressive cancers. Pancreatic ductal adenocarcinoma (PDAC) and triple negative breast cancer (TNBC) are aggressive diseases which lack effective therapies in clinical use. A novel and curative therapy was developed against PDAC and TNBC which involves targeted radiotherapy combined with chemotherapy and DNA damage response inhibition. This project will develop a “p ....EGFR-directed radioimmunotherapy combined with chemotherapy and DNA repair inhibition: development towards clinical application for aggressive cancers. Pancreatic ductal adenocarcinoma (PDAC) and triple negative breast cancer (TNBC) are aggressive diseases which lack effective therapies in clinical use. A novel and curative therapy was developed against PDAC and TNBC which involves targeted radiotherapy combined with chemotherapy and DNA damage response inhibition. This project will develop a “preclinical data package” comprising a biological rationale and preclinical evidence of safety and efficacy that together would justify an early phase clinical trial. This package includes the choice of formulations, mechanism of action and safety studies. This development will have an immediate impact for PDAC and TNBC patients and a future impact on other EGFR-positive cancers.Read moreRead less
Antibiotic resistance is a looming public health crisis. New antibiotics with new mechanisms of action are desperately needed. The long-term goal of this research is to develop new drugs that disarm bacteria to overcome the problem of antibiotic resistance.
Novel Interventions To Address Methamphetamines In Aboriginal Communities, Including A Randomised Trial Of A Web Based Therapeutic Tool Used To Treat Dependence In Clinical Settings.
Funder
National Health and Medical Research Council
Funding Amount
$2,177,908.00
Summary
Methamphetamine use in Aboriginal communities has gained much media attention, despite limited research studies to ascertain the full extent of its use and its impact. We propose a randomised trial of a web based therapeutic tool for use in Aboriginal Medical Services to treat clients using methamphetamines. In addition we will characterise the health and well-being of Aboriginal people who use methamphetamines and trial unique Aboriginal community led interventions to address methamphetamines.
Immuno-polymeric Drugs For Prostate Cancer Therapy
Funder
National Health and Medical Research Council
Funding Amount
$626,995.00
Summary
Prostate cancer is the most common cancer in men over 50 and the second most frequent cause of cancer deaths in Western society. Docetaxel is the first line of chemotherapy when other intervention strategies are unsuccessful, but 30% of patients suffer from severe side-effects. To address this problem, we will utilise carriers for docetaxel that directly target prostate tumours using a novel antibody approach. This increases accumulation at the tumour site while decreasing off-target toxicity.